Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333232 | 0.91 | CTSA (0.40) | CTSA | |
| SCHEMBL4320441 | 0.91 | CTSA (0.39) | CTSAMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL4323851 | 0.90 | CTSA (0.39) | CTSAMEN1KMT2ATP53MAPT | |
| SCHEMBL4343412 | 0.88 | FFAR1 (0.42) | CTSAMAPTFFAR1 | |
| SCHEMBL4337632 | 0.87 | CTSA (0.44) | CTSA | |
| SCHEMBL4337653 | 0.87 | GPR119 (0.41) | CTSAMEN1KMT2AMAPTTDP1 | |
| SCHEMBL4337602 | 0.87 | CTSA (0.41) | CTSAFFAR1 | |
| SCHEMBL4327095 | 0.84 | CTSA (0.39) | CTSATP53SMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4322072 | 0.83 | CTSA (0.40) | CTSAMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL4341790 | 0.81 | CTSA (0.40) | CTSAMEN1KMT2ATDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | CTSA 1028/4885MEN1 3484/4885KMT2A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.